Sign in

ADXN on Nasdaq

Addex Therapeutics Ltd.

Swiss limited company organized under the laws of Switzerland1

In its 2026 annual report (Form 20-F) the company says: “We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partner and internally.”3 Its shares trade on Nasdaq under the symbol ADXN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerADXN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersV81
  • Incorporated inSwitzerland2
  • Business addressChemin Des Mines 9, Geneva, V8 Ch-12022
  • Filer categoryNon-accelerated filer2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Our legal and commercial name is Addex Therapeutics Ltd. We are a Swiss limited company organized under the laws of Switzerland. We were founded in 2002 with an indefinite duration. We are currently registered in Geneva, Switzerland. Our principal executive offices are located at Chemin des Mines 9, CH-1202 Geneva, Switzerland. Our telephone number is +41 884 1555. Investors should contact us for any inquiries through the address and telephone number of our principal executive office, or via our U.S. address at 1968 S Coast Hwy #1915, Laguna Beach, CA 92651. We maintain a website at www.addextherapeutics.com . The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website is not a part of this Annual Report on Form 20-F. The SEC maintains an Internet site that contains reports and other information that we…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$2.8M in 2024+93% since 2018
-$20.0M-$15.0M-$10.0M-$5.0M02018: -$1.4M-$1.4M20182019: -$14.6M-$14.6M2019+925%2020: -$12.2M-$12.2M2020−16%2021: -$15.5M-$15.5M2021+27%2022: -$10.5M-$10.5M2022−32%2023: -$2.2M-$2.2M2023−79%2024: -$2.8M-$2.8M2024+23%
Net income45678$7.1M in 2024
-$30.0M-$20.0M-$10.0M0$10.0M2018: -$1.6M-$1.6M20182019: -$14.8M-$14.8M2019+799%2020: -$12.9M-$12.9M2020−13%2021: -$15.4M-$15.4M2021+19%2022: -$20.8M-$20.8M2022+36%2023: -$10.6M-$10.6M2023−49%2024: $7.1M$7.1M2024

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenue from contract with customer30.0K CHF404.1K CHF1.6M CHF
Other income142.9K CHF5.9K CHF4.2K CHF
Research and development-671.7K CHF-854.3K CHF-1.2M CHF
General and administration-2.3M CHF-2.3M CHF-2.7M CHF
Total operating costs-3.0M CHF-3.2M CHF-3.9M CHF
Operating loss-2.8M CHF-2.8M CHF-2.2M CHF
Finance income26.6K CHF64.0K CHF
Finance expense-15.5K CHF-3.5K CHF-321.1K CHF
Finance result-15.5K CHF23.0K CHF-257.2K CHF
Share of net loss of investments accounted for using the equity method-4.0M CHF-2.2M CHF
Net loss before tax from continuing operations-6.8M CHF-4.9M CHF-2.5M CHF
Income tax expense0 CHF0 CHF0 CHF
Net loss from continuing operations-6.8M CHF-4.9M CHF-2.5M CHF
Net profit / (loss) from discontinued operations (attributable to equity holders of the Group)114.3K CHF12.0M CHF-8.1M CHF
Net profit / (loss) for the period-6.7M CHF7.1M CHF-10.6M CHF
Basic profit / (loss) per share for profit/(loss) attributable to the ordinary equity holders of the Company-0.06 CHF0.07 CHF-0.14 CHF
From continuing operations-0.06 CHF-0.05 CHF-0.03 CHF
From discontinued operations0.12 CHF-0.11 CHF
Diluted profit / (loss) per share for profit/ (loss) attributable to the ordinary equity holders of the Company-0.06 CHF0.07 CHF-0.14 CHF
From continuing operations-0.06 CHF-0.05 CHF-0.03 CHF
From discontinued operations0.12 CHF-0.11 CHF

Compare Addex Therapeutics Ltd. with another company

Corporate structure

Addex Therapeutics Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Addex Therapeutics Ltd.

  • Timothy Mark Dyer Filed SCHEDULE 13D/A on Addex Therapeutics Ltd., latest Sep 4, 2026 (9 filings since Aug 5, 2022)
  • Growth Equity Opportunities Fund IV, LLC Filed SC 13D/A on Addex Therapeutics Ltd., latest Aug 14, 2024 (7 filings since Jan 10, 2022)
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Addex Therapeutics Ltd., latest Feb 16, 2023 (3 filings since Feb 15, 2022)
  • CAXTON CORP Filed SC 13G/A on Addex Therapeutics Ltd., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Goldman Sachs Filed SC 13G/A on Addex Therapeutics Ltd., latest Feb 8, 2023 (2 filings since Feb 14, 2022)
  • New Leaf Biopharma Opportunities I, L.P. Filed SC 13G/A on Addex Therapeutics Ltd., latest Feb 6, 2023 (3 filings since Feb 11, 2022)
  • Credit Suisse Filed SC 13G/A on Addex Therapeutics Ltd., latest Feb 14, 2022
  • Addex Therapeutics Ltd. V8

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Addex Therapeutics Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net1.1K CHF8 Dec 31, 202422.6K CHF8 Dec 31, 2023−95.0%
Operating-lease assets (leased space)41.6K CHF8 Dec 31, 2024330.3K CHF8 Dec 31, 2023−87.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents3.3M CHF8 Dec 31, 20243.9M CHF8 Dec 31, 2023−13.5%
Long-term investments7.1K CHF8 Dec 31, 202454.3K CHF8 Dec 31, 2023−87.0%

Leadership

Who has led Addex Therapeutics Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy Mark Dyer2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerJean-Philippe Rocher named Dec 21, 2021 to Apr 13, 202319
  • Executive OfficerRobert Lutjens named Dec 21, 2021 to Apr 13, 202319
  • DirectorJake Nunn named Dec 21, 2021 to Apr 13, 202319

Timeline

  1. Mar 18, 2026New chief executive Timothy Mark Dyer becomes CEO11

Calendar

Coming up

  1. Dec 3, 2026Reports results for the quarter ending Sep/202620

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

196 filings to the SEC since October 2021: 5 annual reports, 16 insider forms, 27 large holders, 3 private raises, 145 other. The latest 20:

  1. Oct 8, 20266-K EDGAR
  2. Oct 2, 20266-K EDGAR
  3. Sep 28, 20266-K EDGAR
  4. Sep 25, 20266-K EDGAR
  5. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  6. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Sep 4, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Sep 4, 2026SCHEDULE 13D/A EDGAR
  14. Aug 27, 2026SCHEDULE 13D/A EDGAR
  15. Aug 26, 20266-K EDGAR
  16. Jul 8, 20266-K EDGAR
  17. Jun 30, 20266-K EDGAR
  18. Jun 25, 20266-K EDGAR
  19. Jun 5, 20266-K EDGAR
  20. May 15, 202620-F EDGAR

The 196 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 5, 2023Raised $3.7 million in a private offering of equity Form D: 1 investor so far Form D
  2. Jul 22, 2022Raised $4.2 million in a private offering of equity Form D: 1 investor so far Form D
  3. Dec 21, 2021Raised $5.9 million in a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
UBS Group AG47$2680.0%New
SBI Securities Co., Ltd.1$60.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Addex Therapeutics Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAddex Therapeutics Ltd.1
  • CIK0001574232
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company3
  • Incorporated inSwitzerland3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressChemin Des Mines 9, Geneva, V8 CH-12021
  • Phone011412288415551
  • Shares outstanding147,831,814 shares as of Dec 31, 20253
  • AuditorBDO AG, Zurich, Switzerland PCAOB ID 5988; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceSep 24, 20191
  • Filings278 in all: 6-K (126), CORRESP (14), EFFECT (14), SC 13D/A (14), UPLOAD (11), 424B3 (9), SC 13G/A (9), 3 (8)1
    All 32 form types

    4 (8), 20-F (7), 424B5 (7), POS AM (7), F-1 (5), F-1/A (5), SC 13G (5), D (3), SCHEDULE 13D/A (3), 424B4 (2), 6-K/A (2), DRS (2), F-3 (2), NT 20-F (2), S-8 (2), SC 13D (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), DEL AM (1), DRS/A (1), DRSLTR (1), F-6 (1), F-6 POS (1)

  • Latest filingsAnnual report (20-F) May 15, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary SharesADXNNasdaq
Shares, par value CHF 0.01 per share

From the cover page of the 20-F filed May 15, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27